Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
TherapeuticsMD Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific action is assigned to STEINKE, SEAN JAMES, who is identified as the busiest examiner for the portfolio. The concentration of the entire pending workload under a single individual suggests a focused prosecution effort at this stage of the company's patent strategy.
The portfolio's activity is limited to 1 distinct examiner and a distinct art unit. This indicates that the company's current legal challenges are confined to a specific regulatory niche within the broader biotechnology field. Practitioners should note that the busiest examiner pending count matches the total pending office actions for the entire portfolio, meaning there is no diversification of examiner perspectives. This focus requires a precise response strategy tailored to the specific preferences of the assigned official. Having only a distinct examiner involved means that the company's immediate patent outcomes depend on the review of STEINKE, SEAN JAMES. The presence of a distinct art unit further suggests a narrow technical scope for the company's current intellectual property efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18517376 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18517376 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18517376 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE | STEINKE, SEAN JAMES | 1619 | §102§103Other | Non-Final OA | — | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial